Acadia Pharmaceuticals (ACAD)

Acadia’s neurology franchise is led by NUPLAZID, the brand name for pimavanserin. The medicine is approved in the United States for hallucinations and delusions associated with Parkinson’s disease psychosis, a serious neuropsychiatric complication of Parkinson’s disease. NUPLAZID is notable because it was the first FDA-approved treatment specifically for this indication, giving Acadia a differentiated position in a specialised market.

The company’s rare disease business is anchored by DAYBUE, or trofinetide, which is approved for the treatment of Rett syndrome. Rett syndrome is a rare neurodevelopmental disorder that primarily affects girls and can cause severe impairments in communication, movement, and daily functioning. DAYBUE’s approval gives Acadia a commercial presence in a rare disease area with significant unmet medical need.

Beyond its marketed products, Acadia invests in clinical development programmes connected to neurological and neuropsychiatric conditions. Its pipeline includes work in Alzheimer’s disease psychosis and Lewy body dementia psychosis, along with other programmes intended to broaden the company’s reach in disorders affecting cognition, behaviour, and neurological function. For investors, Acadia represents a specialist drug developer whose value is closely tied to commercial execution, regulatory outcomes, and progress in high-need therapeutic categories.